1463-48-5

Usage

Uses

Used in Medicinal Chemistry and Drug Discovery:
8-Benzyl-2,8-diaza-spiro[4.5]decane-1,3-dione serves as a valuable starting material for the synthesis of a variety of pharmaceutical compounds. Its unique spirocyclic structure allows for the development of novel therapeutic agents with potential applications in treating various diseases and conditions.
Used in Synthesis of Novel Spirocyclic Compounds:
8-BENZYL-2,8-DIAZA-SPIRO[4.5]DECANE-1,3-DIONE is utilized as a building block in the preparation of innovative spirocyclic compounds. These newly synthesized compounds may exhibit therapeutic properties, further expanding the scope of available treatments in the pharmaceutical industry.
Used in Research and Development:
8-Benzyl-2,8-diaza-spiro[4.5]decane-1,3-dione is of significant interest to synthetic chemists and researchers who are focused on studying spirocyclic compounds and their properties. Its unique structure provides a foundation for exploring new synthetic pathways and understanding the relationship between structure and biological activity in this class of compounds.
Used in Pharmaceutical Industry:
8-Benzyl-2,8-diaza-spiro[4.5]decane-1,3-dione is used as a key intermediate in the development of new drugs. Its incorporation into drug molecules can potentially enhance their efficacy, selectivity, and pharmacokinetic properties, leading to improved therapeutic outcomes for patients.

InChI:InChI=1/C15H18N2O2/c18-13-10-15(14(19)16-13)6-8-17(9-7-15)11-12-4-2-1-3-5-12/h1-5H,6-11H2,(H,16,18,19)

Upstream product

• 336191-13-0 8-benzyl-2-(4-methoxy-benzyl)-2,8-diaza-spiro[4.5]decane-1,3-dione 
• 40117-92-8 1-benzyl-4-carboxymethyl-piperidine-4-carboxylic acid 
• 1463-52-1 ethyl 2-(1-benzylpiperidin-4-ylidene)-2-cyanoacetate 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 5053-14-5 8-Benzyl-1-oxa-3,8-diaza-spiro[4.5]decan-2-one 
• 86945-27-9 1-benzyl-4-cyanomethylpiperidine-4-carbonitrile 
• 105-56-6 ethyl 2-cyanoacetate 

Downstream Products

• 336191-15-2 8-benzyl-2,8-diazaspiro[4.5]decane 
• 1187036-97-0 benzyl 2,3,4-tri-O-benzyl-6-O-(N-(2-ethyl-2,8-diazaspiro[4,5]decane-1,3-dione)aminocarbonyl)-β-D-glucopyranoside 
• 2079-24-5 2-ethyl-2,8-diaza-spiro[4.5]decane-1,3-dione 
• 1463-47-4 8-benzyl-2-ethyl-2,8-diaza-spiro[4.5]decane-1,3-dione 
• 1061873-16-2 2-methyl-2,8-diazaspiro[4.5]decane 
• 64097-82-1 8-benzyl-2-methyl-2,8-diaza-spiro[4.5]decane 

Relevant academic research and scientific papers

SELF-IMMOLATIVE LINKERS CONTAINING MANDELIC ACID DERIVATIVES, DRUG-LIGAND CONJUGATES FOR TARGETED THERAPIES AND USES THEREOF

The invention provides a therapeutic drug and targeting conjugate, pharmaceutical compositions containing these conjugates in pharmaceutical composition, and uses of these conjugates in anti-neoplastic and other therapeutic regimens. Also provided are novel intermediates thereof. The conjugates provide a therapeutic drug fragment or prodrug fragment bound to a targeting moiety via a linker which comprises a substrate cleavable by a protease such as Cathepsin B. The targeting moiety is a ligand which targets a cell surface molecule, such as a cell surface receptor on an anti-neoplastic cell. The ligand may function solely as a targeting moiety or may itself have a therapeutic effect. Following administration of the therapeutic drug and targeting conjugate of formula I and exposure of the conjugate to the protease specific for the substrate, the linker is cleaved and the targeting moiety is separated from the conjugate, which causes the drug fragment or prodrug fragment to convert to the drug or prodrug. The recited conjugates are useful in anti-neoplastic therapies. Also provided are methods of making the therapeutic drug and targeting conjugates and intermediates thereof, and kits comprising the therapeutic drug and targeting conjugates.

COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS

One aspect of the present invention relates to compounds, compositions and methods for diagnosis and/or treatment of a subject suffering from an amyloidosis-associated pathological condition. In certain embodiments, the imaging and/or therapeutic agents of the instant invention may be administered to a subject for identification and/or treatment of amyloid deposits. A specific imaging method detects amyloid deposits by administering the imaging agent to the subject and detecting the spatial distribution of the agent. Differential accumulation of the agent is indicative of AD or an amyIoidosis-associated pathological condition and can be monitored by using a PET or SPECT camera.

SPIRO-SUBSTITUTED PYRROLOPYRIMIDINES

The invention provides compounds of formula (I) or a pharmaceutically acceptable salt or ester thereof formula (I) wherein the symbols have the meaning as defined in the description. Said compounds are inhibitors of cathepsin K and/or cathepsin S and are useful for the treatment of diseases and medical conditions in which cathepsin K and/or cathepsin S is implicated, e.g. various disorders including neuropathic pain, inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis, multiple sclerosis and tumours.

2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF

The invention relates to pyrrolo pyrimidines of formula (I), wherein Y represents -(CH2)t-O- or -(CH2)r-S-, p is 1 or 2, r is 1, 2 or 3, t is 1, 2 or 3, or Y is -(CH2)j- or -CH=CH-, j is 1 or 2; p is 1 or 2, or Y is -(CH2)f-, f is 1 or 2, p is 1, and the further radicals and symbols have the meaning as defined herein; their preparation, their use as pharmaceuticals, pharmaceutical compositions containing them, the use of such a compound for the manufacture of a pharmaceutical preparation for the treatment of neuropathic pain and to a method for the treatment of such a disease in animals, especially in humans.

Inhibitors of prenyl-protein transferase

The present invention is directed to conformationally constrained compounds which inhibit prenyl-protein transferase and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting prenyl-protein transferase and the prenylation of the oncogene protein Ras.

Serine derived NK1 antagonists 2: A pharmacophore model for arylsulfonamide binding

Modifications to the spirocyclic aryl sulfonamide portion of serine derived NK1 antagonists allow a partial pharmacophore model to be developed.